Zydus Lifesciences Limited has announced Friday, July 24, 2026, as the record date to determine the eligibility of shareholders entitled to receive the final dividend for the financial year ended March 31, 2026. The record date is in compliance with Regulation 42(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's Board, which met on May 19, 2026, had recommended a final dividend of 100%, or Re. 1/- per equity share of Re. 1/- each, subject to the approval of shareholders at the upcoming Annual General Meeting (AGM).

The company has scheduled its Thirty First Annual General Meeting for Tuesday, August 11, 2026, to be held through Video Conference or Other Audio Visual Means. The payment of the dividend, subject to deduction of tax at source, is expected to be made on or around Friday, August 14, 2026, pending shareholder approval at the AGM.

Consolidated Financial Performance

For the financial year 2025-26, Zydus Lifesciences reported total revenue from operations of INR 271,484 million, an increase of 16.8% from INR 232,415 million in the previous year. Consolidated net profit for the year stood at INR 50,400 million, while adjusted net profit rose 15% to INR 54,564 million. For the quarter ended March 31, 2026, revenue from operations was INR 75,870 million, and net profit was INR 12,725 million.

Standalone Financial Performance

On a standalone basis, the company reported total revenue from operations of INR 114,840 million for FY26, compared to INR 151,163 million in the prior year. Net profit for the year stood at INR 35,598 million, against INR 57,749 million in the previous year. The quarter ended March 31, 2026, recorded standalone revenue from operations of INR 37,409 million and net profit of INR 17,220 million.

Zydus Lifesciences Limited announced that its subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc., a Nasdaq-listed U.S. specialty pharmaceutical company. The acquisition is being executed through Zydus Worldwide's wholly owned acquisition subsidiary, Zara Merger Sub Inc. The transaction is valued at USD 23.50 per share in cash, representing a total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method. The deal has been approved by the Boards of Directors of both Zydus Worldwide and Assertio.

Transaction Structure and Key Terms

The following table summarises the key parameters of the proposed acquisition:

The transaction is structured as a tender offer to be followed by a merger, pursuant to which Zara Merger Sub Inc. will merge with and into Assertio, with Assertio continuing as the surviving corporation. The tender offer is expected to commence within five business days following the date of the merger agreement. The proposed acquisition does not fall within related party transactions, and none of the promoter, promoter group, or group companies have any interest in the proposed acquisition.

About Assertio Holdings and Its Key Asset

Assertio is a U.S.-based specialty pharmaceutical company headquartered in Lake Forest, Illinois, with established commercial capabilities for marketing and distribution of differentiated products. Its primary asset is ROLVEDON® (eflapegrastim-xnst), approved as a BLA by the USFDA as a long-acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. ROLVEDON® is administered once per chemotherapy cycle in the oncology supportive care market. On April 8, 2026, Assertio completed the sale of certain other products to Cosette Pharmaceuticals Inc. The adjusted turnover for ROLVEDON® — the surviving product — for the past three calendar years is as follows:

Note 1: ROLVEDON® was acquired by Assertio on July 31, 2023; the turnover for CY 2023 is for a period of 5 months.

Strategic Rationale

The proposed acquisition is in line with Zydus's strategic objective of building a specialty oncology company in the U.S. Assertio's commercial infrastructure offers several key advantages:

• 170+ community oncology accounts providing an established market presence
• Buy-and-bill infrastructure offering a ready-made base to build a broader oncology platform
• An approved oncology asset in ROLVEDON® with a growing revenue trajectory
• An immediate U.S. specialty oncology commercial footprint to support portfolio expansion

Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited, stated: "This transaction represents a strategic step in strengthening our specialty and oncology footprint in the U.S. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable specialty businesses globally."

Advisors and Regulatory Requirements

The transaction is subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock, as well as requisite regulatory approvals. Paul Weiss, Rifkind, Wharton & Garrison LLP is serving as legal counsel to Zydus. Moelis & Company LLC is serving as financial advisor to Assertio, and Gibson, Dunn & Crutcher LLP is serving as its legal counsel. Upon successful completion of the transaction, Assertio will be delisted from Nasdaq.